128 related articles for article (PubMed ID: 35421669)
21. miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP.
Zhang L; Wang Y; Wang L; Yin G; Li W; Xian Y; Yang W; Liu Q
Biomed Pharmacother; 2018 Nov; 107():424-432. PubMed ID: 30103114
[TBL] [Abstract][Full Text] [Related]
22. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.
Huang DH; Jian J; Li S; Zhang Y; Liu LZ
Int J Mol Med; 2019 Dec; 44(6):2113-2122. PubMed ID: 31638175
[TBL] [Abstract][Full Text] [Related]
23. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Ishijima N; Kanki K; Shimizu H; Shiota G
Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
[TBL] [Abstract][Full Text] [Related]
24. Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Chang HL; Chen HA; Bamodu OA; Lee KF; Tzeng YM; Lee WH; Tsai JT
Toxicol In Vitro; 2018 Sep; 51():74-82. PubMed ID: 29698666
[TBL] [Abstract][Full Text] [Related]
25. CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling.
Yang L; Xue H; Sun Y; Zhang L; Xue F; Ge R
Cell Death Dis; 2020 Jul; 11(7):605. PubMed ID: 32732872
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown.
Gao Y; Gong Y; Liu Y; Xue Y; Zheng K; Guo Y; Hao L; Peng Q; Shi X
Acta Histochem; 2023 Jan; 125(1):151987. PubMed ID: 36473310
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Ras protein activator like 2 produces antitumor effects in gastric cancer via the suppression of YAP1 activation.
Hu Y; Zhang P; Shi Y; Dong X; Wu Y; Dong D; Li E; Fan Y
Environ Toxicol; 2022 Mar; 37(3):527-538. PubMed ID: 34826200
[TBL] [Abstract][Full Text] [Related]
28. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
29. Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling.
Zhao G; Song Y; Dong L; Shi H; Li H; Yang L; Wang J
Biochem Biophys Res Commun; 2019 Oct; 517(4):722-728. PubMed ID: 31395338
[TBL] [Abstract][Full Text] [Related]
30. System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma.
Xu JH; Guan YJ; Qiu ZD; Zhang X; Zi LL; Zhou Y; Chen C; Yu J; Zhang YC; Wang WX
Oxid Med Cell Longev; 2021; 2021():6485871. PubMed ID: 34795841
[TBL] [Abstract][Full Text] [Related]
31. Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.
Peng Q; Hao L; Guo Y; Zhang Z; Ji J; Xue Y; Liu Y; Li C; Lu J; Shi X
J Nat Med; 2023 Jan; 77(1):28-40. PubMed ID: 36068393
[TBL] [Abstract][Full Text] [Related]
32. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
33. RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.
Ahn EY; Kim JS; Kim GJ; Park YN
Mol Cancer Res; 2013 Jul; 11(7):748-58. PubMed ID: 23594797
[TBL] [Abstract][Full Text] [Related]
34. MiR-21-3p Promotes Hepatocellular Carcinoma Progression
Hong Y; Ye M; Wang F; Fang J; Wang C; Luo J; Liu J; Liu J; Liu L; Zhao Q; Chang Y
Front Oncol; 2021; 11():642030. PubMed ID: 33763375
[TBL] [Abstract][Full Text] [Related]
35. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
36. miR-424-5p Regulates Hepatoma Cell Proliferation and Apoptosis.
Piao L; Wang F; Wang Y; Yang Z; Li Q; Cui L; Yu Q
Cancer Biother Radiopharm; 2019 Apr; 34(3):196-202. PubMed ID: 30676784
[TBL] [Abstract][Full Text] [Related]
37. Upregulator of cell proliferation predicts poor prognosis in hepatocellular carcinoma and contributes to hepatocarcinogenesis by downregulating FOXO3a.
Xie C; Song LB; Wu JH; Li J; Yun JP; Lai JM; Xie DY; Lin BL; Yuan YF; Li M; Gao ZL
PLoS One; 2012; 7(7):e40607. PubMed ID: 22815774
[TBL] [Abstract][Full Text] [Related]
38. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
[TBL] [Abstract][Full Text] [Related]
39. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
40. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
